Q2 2024 Earnings Summary
- Strong volume growth expected to continue: CYH is experiencing robust same-store volume growth in both inpatient and outpatient services, driven by investments in capacity expansion, successful physician recruitment, and operational improvements like a 5% improvement in length of stay over the prior year. They believe the fundamentals are solid and expect this momentum to continue into the second half of the year, aligning with historical trends where the back half is traditionally stronger.
- Potential material benefits from new Medicaid supplemental programs: CYH anticipates material benefits from new Medicaid supplemental payment programs in New Mexico and Tennessee, although these programs are not yet approved. Once approved, these programs could provide significant additional revenue and enhance financial performance.
- Progress on divestitures to strengthen the balance sheet: Despite the FTC blocking the Novant deal, CYH is proceeding with other divestitures involving out-of-state buyers and does not anticipate regulatory headwinds in completing these transactions. They expect combined potential proceeds of more than $1 billion, which could strengthen the balance sheet and provide capital for redeployment.
- Increasing 'Other Operating Expenses' due to higher provider tax payments: The company reported a significant increase in other operating expenses, primarily driven by higher provider tax payments. This increase may impact margins and cause earnings variability due to timing differences between expense recognition and associated supplemental revenue.
- Uncertainty around supplemental payment programs in New Mexico and Tennessee: The company is hesitant to quantify the potential benefits from new supplemental payment programs, as they are not yet approved by CMS. There is a risk that these materially beneficial programs may not be approved or may be delayed, affecting expected financial gains.
- Potential challenges in asset divestitures due to regulatory scrutiny: Following the abrupt termination of the sale of North Carolina hospitals to Novant Health due to FTC intervention, there may be concerns about the company's ability to complete other planned divestitures. This could hinder the company's strategy to generate over $1 billion in proceeds and redeploy capital.
-
Asset Sales and FTC Objections
Q: Can you update us on asset sales amid FTC issues?
A: Kevin Hammons said that despite the FTC's objections to the Novant deal, they don't see headwinds in completing other divestitures. Buyers are now mostly out-of-market and out-of-state, reducing FTC concerns. For example, the Cleveland, Tennessee deal involves a nonprofit based in Georgia. -
Potential DPP Payments Benefit
Q: Any update on the material benefit from DPP payments?
A: Kevin stated they believe the New Mexico and Tennessee DPP programs will be materially beneficial, but are hesitant to quantify since approvals by CMS are pending. -
Managed Care Rates and Labor Costs
Q: Are managed care rates helping offset labor costs?
A: Kevin noted that new contracted rates for next year are similar to the past two years, with rate increases about 100 basis points above traditional levels, reflecting some incremental labor costs flowing through. -
Same-Store Volume Growth Outlook
Q: What's driving same-store volume growth ahead?
A: Tim highlighted investments in growth projects like new beds in Knoxville, successful physician recruitment, and a 5% improvement in length of stay. These bolster procedural volumes and overall capacity, positioning them well for upcoming quarters. -
Higher Demand Expectations
Q: How does higher demand affect your outlook?
A: Kevin expects demand to continue increasing, with the back half of the year historically better and guidance reflecting higher revenue and EBITDA, heavily weighted to Q4. They see better balanced growth between commercial and government-insured patients, expecting this trend to continue. -
Impact of Enhanced Subsidies Expiration
Q: Thoughts on exchange volumes with subsidies ending?
A: Tim acknowledged the expiration of enhanced subsidies in 2026 is a wildcard dependent on politics. They remain active in advocacy efforts to highlight the importance of exchange affordability and are involved in lobbying to continue funding. -
Cash Flow Timing Issues
Q: Any timing issues affecting cash flow this quarter?
A: Kevin explained a significant timing issue due to their annual $65–$70 million 401(k) match payment made in Q2. This is recouped in the back half as a noncash expense, making Q4 typically their strongest cash flow quarter. -
Observation Status and Exchange Volumes
Q: How are observation status changes impacting results?
A: Kevin said they've reduced observations and increased short-stay admissions, beneficially impacting results. They see a decrease in Medicaid volumes with an offsetting increase in commercial business, likely from exchange plans, without a rise in self-pay patients. -
Inpatient and Outpatient Volume Shifts
Q: What drove shifts between inpatient and outpatient volumes?
A: Kevin attributed inpatient growth to investments like the new bed tower in Knoxville and converting observations to admissions. Outpatient growth is also strong due to targeted investments. Tim added that growth is balanced, with strategic outpatient access expansions through joint ventures to capture more market spend.